{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:14:59Z","timestamp":1762866899264,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11096-016-0343-0","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T02:54:55Z","timestamp":1468896895000},"page":"1142-1148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2592-435X","authenticated-orcid":false,"given":"Laida","family":"Elberd\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Outeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Paradela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"Fern\u00e1ndez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"343_CR1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"NE Aikawa","year":"2010","unstructured":"Aikawa NE, de Carvalho JF, Almeida Silva CA, Bonf\u00e1 E. Immunogenicity of anti-TNF-\u03b1 agents in autoinmune diseases. Clin Rev Allergy Immunol. 2010;38:82\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"343_CR2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","volume":"169","author":"SK Mahil","year":"2013","unstructured":"Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept, a single centre, cohort study. Br J Dermatol. 2013;169:306\u201313.","journal-title":"Br J Dermatol"},{"key":"343_CR3","first-page":"171","volume":"148","author":"E Cozzani","year":"2013","unstructured":"Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients a preliminary study. G Ital Dermatol Venereol. 2013;148:171\u20134.","journal-title":"G Ital Dermatol Venereol"},{"key":"343_CR4","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of antiTNF therapy in immune-mediated inflammatory diseases a systematic review of the literature with a metaanalysis. Ann Rheum Dis. 2013;72:1947\u201355.","journal-title":"Ann Rheum Dis"},{"key":"343_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Schouwenburg Van","year":"2013","unstructured":"Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164\u201372.","journal-title":"Nat Rev Rheumatol"},{"key":"343_CR6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429\u201335.","journal-title":"Clin Rheumatol"},{"key":"343_CR7","first-page":"31","volume":"33","author":"B Haraoui","year":"2006","unstructured":"Haraoui B, Cameron L, Ouellet M, White B. Antiinfliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31\u20136.","journal-title":"J Rheumatol"},{"key":"343_CR8","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","volume":"74","author":"DY Chen","year":"2015","unstructured":"Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74:e16.","journal-title":"Ann Rheum Dis"},{"key":"343_CR9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","volume":"69","author":"GM Bartelds","year":"2010","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis. 2010;69:817\u201321.","journal-title":"Ann Rheum Dis"},{"key":"343_CR10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711\u20135.","journal-title":"Arthritis Rheum"},{"key":"343_CR11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10067-008-0866-4","volume":"27","author":"AE Bijl Van der","year":"2008","unstructured":"Van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021\u20138.","journal-title":"Clin Rheumatol"},{"key":"343_CR12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","volume":"70","author":"A Jamnitski","year":"2011","unstructured":"Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284\u20138.","journal-title":"Ann Rheum Dis"},{"key":"343_CR13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nu\u00f1o L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445\u201352.","journal-title":"Rheumatology"},{"key":"343_CR14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","volume":"137","author":"K Karmiris","year":"2009","unstructured":"Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in crohn\u2019s disease. Gastroenterology. 2009;137:1628\u201340.","journal-title":"Gastroenterology"},{"issue":"80\u20134","key":"343_CR15","first-page":"e2","volume":"12","author":"X Roblin","year":"2014","unstructured":"Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(80\u20134):e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"343_CR16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2004;2:542\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"343_CR17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D\u2019 Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348:601\u20138.","journal-title":"N Engl J Med"},{"key":"343_CR18","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2008;28:1122\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"343_CR19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","volume":"105","author":"W Afif","year":"2010","unstructured":"Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133\u20139.","journal-title":"Am J Gastroenterol"},{"key":"343_CR20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","volume":"59","author":"CH Seow","year":"2010","unstructured":"Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49\u201354.","journal-title":"Gut"},{"key":"343_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","volume":"150","author":"SP Menting","year":"2014","unstructured":"Menting SP, van L\u00fcmig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis: one-year follow up. JAMA Dermatol. 2014;150:130\u20136.","journal-title":"JAMA Dermatol"},{"key":"343_CR22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1346-8138.12093","volume":"40","author":"Y Matsumoto","year":"2013","unstructured":"Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol. 2013;40:389\u201392.","journal-title":"J Dermatol"},{"key":"343_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11096-014-0062-3","volume":"37","author":"L Elberd\u00edn","year":"2015","unstructured":"Elberd\u00edn L, Outeda M, Salvador P, Paradela S, Fern\u00e1ndez-Torres RM, Iglesias R, et al. Infliximab drug and antibody levels in patients with dermatological conditions. Int J Clin Pharm. 2015;37:320\u20136.","journal-title":"Int J Clin Pharm"},{"key":"343_CR24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1346-8138.2010.00882.x","volume":"37","author":"E Adisen","year":"2010","unstructured":"Adisen E, Aral A, Aybay C, G\u00fcrer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients. pilot study. J Dermatol. 2010;37:708\u201313.","journal-title":"J Dermatol"},{"key":"343_CR25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2340\/00015555-1376","volume":"92","author":"MW Meyer","year":"2012","unstructured":"Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92:362\u20134.","journal-title":"Acta Derm Venereol"},{"key":"343_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1346-8138.2012.01679.x","volume":"40","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39\u201342.","journal-title":"J Dermatol"},{"key":"343_CR27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","volume":"9","author":"L Hsu","year":"2013","unstructured":"Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9:949\u201358.","journal-title":"Expert Rev Clin Immunol"},{"key":"343_CR28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","volume":"170","author":"L Hsu","year":"2014","unstructured":"Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis a systematic review. Br J Dermatol. 2014;170:261\u201373.","journal-title":"Br J Dermatol"},{"key":"343_CR29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48:1267\u201381.","journal-title":"J Pharm Biomed Anal"},{"key":"343_CR30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1515\/cclm-2012-0050","volume":"50","author":"F Llinares-Tello","year":"2012","unstructured":"Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ram\u00edrez CS, Heredia ES, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med. 2012;50:1845\u20137.","journal-title":"Clin Chem Lab Med"},{"key":"343_CR31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0001-7310(09)71257-8","volume":"100","author":"L Puig","year":"2009","unstructured":"Puig L, Carrascosa JM, Daud\u00e9n E, S\u00e1nchez-Carazo JL, Ferr\u00e1ndiz C, S\u00e1nchez-Rega\u00f1a M, et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009;100:386\u2013413.","journal-title":"Actas Dermosifiliogr"},{"key":"343_CR32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","volume":"71","author":"A Jamnitski","year":"2012","unstructured":"Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71:88\u201391.","journal-title":"Ann Rheum Dis"},{"key":"343_CR33","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3899\/jrheum.111522","volume":"39","author":"CI Da\u00efen","year":"2012","unstructured":"Da\u00efen CI, Da\u00efen V, Parussini E, Dupuy AM, Combe B, Morel J. Etanercept concentration in patients with AR and its potencial influence on treatment decisions: a pilot study. J Rheumatol. 2012;39:1533\u20138.","journal-title":"J Rheumatol"},{"key":"343_CR34","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.4049\/jimmunol.1502195","volume":"196","author":"I Detrez","year":"2016","unstructured":"Detrez I, Brouwers E, Peeters M, Geukens N, de Vlam K, Gils A. Characterization and application of a unique panel of monoclonal antibodies generated against etanercept. J Immunol. 2016;196:2879\u201384.","journal-title":"J Immunol"},{"key":"343_CR35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","volume":"68","author":"MK Vries De","year":"2009","unstructured":"De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:531\u20135.","journal-title":"Ann Rheum Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-016-0343-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-016-0343-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:42:23Z","timestamp":1498315343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-016-0343-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s11096-016-0343-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}